Table 1.
Patient demographics and tumor characteristics
| CRC patients | Healthy donors | ||
|---|---|---|---|
| (N = 71) | (N = 19) | P value | |
| Age* | 0.06 | ||
| Mean (years) | 65.6 | 55.6 | |
| Range | 25–85 | 22–83 | |
| Sex | 0.56 | ||
| Female | 32 (45.1%) | 10 (52.6%) | |
| Male | 39 (54.9%) | 9 (47.4%) | |
| Tumor location | |||
| Colon | 59 (83.1%) | ||
| Rectum | 12 (16.9%) | ||
| Tumor stage | |||
| Stage 0 | 4 (5.6%) | ||
| Stage I | 10 (14.1%) | ||
| Stage II | 22 (35.2%) | ||
| Stage III | 22 (33.8%) | ||
| Stage IV | 8 (11.3%) | ||
| Tumor differentiation grade | |||
| Well/moderate | 55 (77.5%) | ||
| Poor | 13 (18.3%) | ||
| Unknown | 3 (4.2%) | ||
| Lymph node invasion | |||
| Yes | 30 (56.3%) | ||
| No | 40 (42.3%) | ||
| Unknown | 1 (1.4%) | ||
| Neoadjuvant radiotherapy | |||
| Yes | 10 (14.1%) | ||
| No | 61 (85.9%) | ||
| Adjuvant chemotherapy | |||
| Yes | 27 (38.0%) | ||
| No | 44 (62.0%) | ||
In this study, the immunophenotype of peripheral blood immune cell profiles was investigated in 71 CRC patients and 19 healthy donors
*Age at time of surgery